Cargando…

Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors

Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart and kidney failure in patients with type 2 diabetes, possibly due to diuretic effects. Previous non-placebo-controlled studies with SGLT2 inhibitors observed changes in volume markers in healthy individuals and in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eickhoff, Mie K., Dekkers, Claire C. J., Kramers, Bart J., Laverman, Gozewijn Dirk, Frimodt-Møller, Marie, Jørgensen, Niklas Rye, Faber, Jens, Danser, A. H. Jan, Gansevoort, Ron T., Rossing, Peter, Persson, Frederik, Heerspink, Hiddo J. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616433/ https://www.ncbi.nlm.nih.gov/pubmed/31159350 http://dx.doi.org/10.3390/jcm8060779

Ejemplares similares

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Improvement of Sodium Status to Optimize the Efficacy of Renin-Angiotensin System Blockade
por: Laverman, Gozewijn D., et al.
Publicado: (2011)

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND
por: Sen, Taha, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
por: van der Aart-van der Beek, Annemarie B., et al.
Publicado: (2021)

The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis
por: Scholtes, Rosalie A., et al.
Publicado: (2019)

Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial
por: Slagman, Maartje C J, et al.
Publicado: (2011)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial
por: Curovic, Viktor Rotbain, et al.
Publicado: (2023)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
por: Rotbain Curovic, Viktor, et al.
Publicado: (2022)

Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions
por: Eickhoff, Mie Klessen, et al.
Publicado: (2020)

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018)

Revisiting the Brain Renin-Angiotensin System—Focus on Novel Therapies
por: Ren, Liwei, et al.
Publicado: (2019)

Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus
por: Pena, Michelle J., et al.
Publicado: (2016)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Megalin: a Novel Determinant of Renin-Angiotensin System Activity in the Kidney?
por: Sun, Yuan, et al.
Publicado: (2020)

Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels
por: Gant, Christina M., et al.
Publicado: (2017)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

High Renin Concentrations in Severe COVID-19 Are Indicative for a Hypo–Renin–Angiotensin-System State
por: Akin, Sakir, et al.
Publicado: (2022)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
por: Wheeler, David C, et al.
Publicado: (2021)

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review
por: Persson, Frederik, et al.
Publicado: (2016)

Mitigating risk of aldosterone in diabetic kidney disease
por: Frimodt-Møller, Marie, et al.
Publicado: (2020)

Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease
por: Persson, Frederik, et al.
Publicado: (2019)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
por: Koshino, Akihiko, et al.
Publicado: (2023)

What’s new in the renin-angiotensin system?: What’s new in the renin-angiotensin system?
por: Smith, A. I., et al.
Publicado: (2004)

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
por: Vart, Priya, et al.
Publicado: (2022)

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial
por: Kwakernaak, A. J., et al.
Publicado: (2017)

Megalin, Proton Pump Inhibitors and the Renin–Angiotensin System in Healthy and Pre-Eclamptic Placentas
por: Sun, Yuan, et al.
Publicado: (2021)

The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet
por: Scholtes, Rosalie A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3bdgd995ip8fvafffe7ebleo6n